We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.9992 0.2113% AAPL 231.83 0.0216% NVDA 138.895 2.3394% GOOGL 163.53 -0.9869% GOOG 165.1 -0.9836% AMZN 187.78 0.4762% META 578.1245 0.2314% AVGO 183.5976 3.8331% TSLA 220.4371 -0.4034% TSM 207.9713 10.9299% LLY 917.515 -0.5652% V 289.845 0.8086% JPM 224.705 0.4762% UNH 568.2 -0.5496% NVO 118.43 0.3389% WMT 80.845 -0.4617% LVMUY 131.3 0.6439% XOM 120.36 -0.2486% LVMHF 659.0 1.0345% MA 513.11 -0.1867%

Notable Labs Inc.

Healthcare US NTBL

0.5036USD
0.26(108.10%)

Last update at 2024-10-17T18:55:00Z

Day Range

0.290.55
LowHigh

52 Week Range

0.7111.20
LowHigh

Fundamentals

  • Previous Close 0.24
  • Market Cap11.70M
  • Volume106785640
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.55500M
  • Revenue TTM0.13M
  • Revenue Per Share TTM0.009
  • Gross Profit TTM 0.00800M
  • Diluted EPS TTM-1.61

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -11.26400M -14.40700M -16.05200M -24.22500M -19.39600M
Minority interest - - - - -
Net income -11.26400M -14.40700M -16.05200M -24.22500M -19.39600M
Selling general administrative 10.06M 5.16M 5.73M - -
Selling and marketing expenses - - - - -
Gross profit 0.11M -1.15400M -1.33600M -0.66600M -0.87900M
Reconciled depreciation 0.26M 0.32M 0.33M - -
Ebit -19.60700M -12.92400M -16.91400M -24.48300M -20.08200M
Ebitda -19.35000M -12.60100M -16.58800M -23.28900M -18.86300M
Depreciation and amortization 0.26M 0.32M 0.33M 1.19M 1.22M
Non operating income net other - - - - -
Operating income -14.65700M -12.92400M -16.91400M -24.48300M -20.08200M
Other operating expenses 14.97M 12.93M 17.20M 25.41M 20.64M
Interest expense - - - 0.10M 0.18M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.95000M - - -0.00000M -0.00000M
Total revenue 0.31M 0.00800M 0.28M 0.92M 0.56M
Total operating expenses 14.77M 12.93M 17.20M 23.82M 19.20M
Cost of revenue 0.20M 1.16M 1.62M 1.59M 1.44M
Total other income expense net 3.39M -1.48300M 0.86M 0.26M 0.69M
Discontinued operations - - - - -
Net income from continuing ops -11.26400M -14.40700M -16.05200M - -
Net income applicable to common shares - -14.40700M -16.05200M - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 19.54M 5.51M 8.49M 41.71M 49.01M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.57M 1.27M 1.34M 1.23M 0.61M
Total liab 4.43M 42.48M 62.43M 10.79M 12.98M
Total stockholder equity 15.11M -36.96800M -53.94300M 30.92M 36.02M
Deferred long term liab - - - - -
Other current liab 0.42M - - 4.28M 4.18M
Common stock 0.79M 0.01M 0.00600M 0.11M 0.07M
Capital stock 0.79M 0.01M 0.00600M - -
Retained earnings -82.30800M -71.04400M -56.63700M -232.15300M -207.92800M
Other liab - - - - -
Good will - - - - -
Other assets - 0.22M 0.36M - -
Cash 11.82M 1.58M 2.40M 13.34M 9.44M
Cash and equivalents - - - - -
Total current liabilities 2.74M 2.01M 2.34M 7.46M 8.67M
Current deferred revenue - - - 0.72M 0.39M
Net debt -9.77600M - - -10.80700M -6.49500M
Short term debt 0.52M - - 0.50M 0.77M
Short long term debt - - - - -
Short long term debt total 2.05M - - 2.53M 2.94M
Other stockholder equity 96.52M - - 252.56M 235.97M
Property plant equipment - 0.80M 1.55M - -
Total current assets 15.47M 2.99M 5.07M 31.99M 37.78M
Long term investments - - - - -
Net tangible assets - -36.96800M -53.94300M - -
Short term investments - 0.00000M 0.87M 17.11M 27.10M
Net receivables 0.19M 0.00800M 0.05M 0.32M 0.63M
Long term debt - - 1.04M - -
Inventory 2.89M - - - -
Accounts payable 1.80M 0.75M 0.65M 1.96M 3.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.11M - - 10.40M 7.90M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.72M 0.22M 0.36M 0.59M 0.62M
Deferred long term asset charges - - - - -
Non current assets total 4.07M 2.52M 3.41M 9.71M 11.23M
Capital lease obligations 2.05M 0.36M 0.81M - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 15.54M 0.87M 16.70M - -
Change to liabilities - 0.10M 0.05M - -
Total cashflows from investing activities - 0.92M 14.76M - -
Net borrowings - - 1.04M - -
Total cash from financing activities 7.82M 9.90M 1.07M 17.07M -0.35900M
Change to operating activities - 0.01000M 0.04M - -
Net income -11.26400M -14.40700M -16.05200M -24.22500M -19.39600M
Change in cash 10.24M -0.82000M 0.77M 3.90M -19.91100M
Begin period cash flow 1.58M 2.40M 1.63M 9.44M 29.35M
End period cash flow 11.82M 1.58M 2.40M 13.34M 9.44M
Total cash from operating activities -13.71600M -11.64200M -15.05300M -23.37800M -13.08900M
Issuance of capital stock 3.98M 5.81M 0.00000M - -
Depreciation 0.26M 0.32M 0.33M 1.19M 1.22M
Other cashflows from investing activities - - -1.50000M - -
Dividends paid - - - - -
Change to inventory - - -0.12900M - -
Change to account receivables - - 0.13M -0.12900M -
Sale purchase of stock - - - - -
Other cashflows from financing activities 3.90M 4.01M 14.76M 9.89M -6.10000M
Change to netincome - 2.33M 0.58M - -
Capital expenditures 0.07M 0.04M 0.44M 0.05M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.69800M 0.11M 0.10M -2.07600M 2.62M
Stock based compensation 0.59M 0.58M 0.78M - -
Other non cash items 0.61M 0.23M 0.60M 5.62M 2.77M
Free cash flow -13.78100M -11.68300M -15.49400M -23.42900M -13.16200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NTBL
Notable Labs Inc.		 0.26 108.10% 0.50 - - 90.01 - 1310.21 -0.8318
NVO
Novo Nordisk A/S		 0.40 0.34% 118.43 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 2.04 1.75% 118.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 11.16 2.29% 498.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -6.665 0.66% 1001.29 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

Notable Labs Inc.

320 Hatch Drive, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Dr. Thomas A. Bock M.B.A., M.D. CEO & Director NA
Mr. Scott Alan McPherson CFE, CPA, CVA Chief Financial Officer 1961
Dr. Joseph P. Wagner Ph.D. Chief Scientific Officer NA
Dr. Glenn C. Michelson M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.